Abstract

Background:Psoriasis is a chronic inflammatory skin disease that not fully understood till now. Many treatment options has been implicated. Omentin 1 is anew marker implicated in many diseases.

Objectives:To show association betweenserum level of Omentin-1 in psoriatic patients and its correlation with psoriasis area and severity index (PASI) score before and after treatment with narrow band ultraviolet B phototherapy (NBUVB) and Acitretin.

Patients and Methods:This randomized controlled trial was carried out on forty psoriatic cases and twenty normal controls. Patients were randomized into two groups, 1st, NBUVB group:included 20 patients treated with NBUVB. 2nd, acitretin group: included 20 patients treated with acitretin. 3rd group is a control group: included 20 normal healthy individual. Patients were subjected to blood sampling to detect serum levels of omentin-1 by ELISA.

Results:There was a highly significant difference in omentin 1 level (p<0.001) between patients and control group. A significance difference in serum levels of omentin-1 before and after treatment in both groups (p<0.001). No significant difference was found between both groups after treatment (p = 0.334). PASI score was significantly reduced in both groups with (p < 0.001) with significant reduction in Acitretin group (p < 0.001).

Conclusion:Omentin-1 levels is significantly lowered in psoriasiscompared to the controls. Omentin-1 levels significantly increased after NB-UVB and Acitretin therapy. Omentin-1 may be a future marker for psoriasis help in diagnosis and treatment.